# IN VITRO METABOLISM AND NON-CLINICAL ADME STUDIES IDIQ CONTRACT. POP 9/27/21-9/26/26. NTE $3.5 MILLION.  TASK ORDER 03 OBLIGATED IN THE AMOUNT OF $136

> **NIH NIH N01** · SRI INTERNATIONAL · 2022 · $165,694

## Abstract

The Division of Therapeutics and Medical Consequences (DTMC) of the National Institute on Drug Abuse (NIDA)
supports research and development of new medications for the treatment of drug addiction. Medication development
involves in vitro evaluations, nonclinical pharmacology and toxicology studies, pharmaceutical development, and
clinical evaluation of new medications for treating addiction.

## Key facts

- **NIH application ID:** 10710585
- **Project number:** 75N95021D00025-P00002-9999-2
- **Recipient organization:** SRI INTERNATIONAL
- **Principal Investigator:** MARY BASTIDA
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $165,694
- **Award type:** —
- **Project period:** 2021-09-27 → 2026-09-26

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10710585

## Citation

> US National Institutes of Health, RePORTER application 10710585, IN VITRO METABOLISM AND NON-CLINICAL ADME STUDIES IDIQ CONTRACT. POP 9/27/21-9/26/26. NTE $3.5 MILLION.  TASK ORDER 03 OBLIGATED IN THE AMOUNT OF $136 (75N95021D00025-P00002-9999-2). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10710585. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*